Hybrid promoters
The invention includes hybrid promoters containing an LTR component and a promoter component, transgenic avians containing the hybrid promoters in their genome and methods of making the transgenic avians.
1 . A hybrid promoter comprising an LTR component and a promoter component that is 3′ of LTR component.
2 . The hybrid promoter of claim 1 wherein the 3′ end of the LTR component is linked to the 5′ end of the promoter component.
3 . The hybrid promoter of claim 1 wherein the hybrid promoter facilitates transcription of a coding sequence by an amount greater than that of the promoter component.
4 . The hybrid promoter of claim 1 wherein the promoter is contained in a vector.
5 . The hybrid promoter of claim 1 wherein the promoter is contained in a retroviral vector.
6 . The hybrid promoter of claim 1 wherein the promoter is contained in a SIN retroviral vector.
7 . The hybrid promoter of claim 1 wherein the promoter is contained in a retroviral vector and the LTR component of the hybrid promoter serves as the 5′ LTR of the vector.
8 . The hybrid promoter of claim 1 wherein the LTR component comprises a portion of an LTR of a virus selected from the group consisting of Rous Sarcoma Virus (RSV), Murine Leukemia Virus (MLV), Molony Murine Sarcoma Virus (MMSV), Moloney Murine Leukemia Virus (MMLV), Avian Leokosis Virus (ALV) and lentivirus (e.g., human immunodeficiency virus (HIV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV) and simian immunodeficiency virus (SIV).
9 . The hybrid promoter of claim 1 wherein the promoter component comprises a portion of an promoter selected from the group consisting of CMV promoter, ef-1a promoter, PGK promoter and beta actin promoter.
10 . The hybrid promoter of claim 1 wherein the promoter is operably linked to a nucleotide coding sequence.
11 . The hybrid promoter of claim 10 wherein the nucleotide coding sequence encodes a therapeutic protein.
12 . A transgenic avian containing a hybrid promoter comprising an LTR component and a promoter component.
13 . The transgenic avian of claim 12 comprising a tubular gland cell containing the hybrid promoter.
14 . The transgenic avian of claim 12 wherein the avian is selected from the group consisting of chicken, turkey, duck, goose, quail, pheasants, parrots, finches, hawks, crows and ratites including ostrich, emu and cassowary.
15 . The transgenic avian of claim 12 wherein the 3′ end of the LTR component is linked to the 5′ end of the promoter component.
16 . The transgenic avian of claim 12 wherein the hybrid promoter facilitates transcription of a coding sequence by an amount greater than that of the promoter component.
17 . The transgenic avian of claim 12 wherein the promoter is contained in a vector.
18 . The transgenic avian of claim 12 wherein the promoter is contained in a retroviral vector.
19 . The transgenic avian of claim 12 wherein the promoter is contained in a SIN retroviral vector.
20 . The transgenic avian of claim 12 wherein the promoter is contained in a retroviral vector and the LTR component of the hybrid promoter serves as the 5′ LTR of the vector.
21 . The transgenic avian of claim 12 wherein the LTR component comprises a portion of an LTR of a virus selected from the group consisting of Rous Sarcoma Virus (RSV), Murine Leukemia Virus (MLV), Molony Murine Sarcoma Virus (MMSV), Moloney Murine Leukemia Virus (MMLV), Avian Leokosis Virus (ALV) and lentivirus (e.g., human immunodeficiency virus (HIV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV) and simian immunodeficiency virus (SIV).
22 . The transgenic avian of claim 12 wherein the promoter component comprises a portion of an promoter selected from the group consisting of CMV promoter, ef-1a promoter, PGK promoter and beta actin promoter.
23 . The hybrid promoter of claim 12 wherein the promoter is operably linked to a nucleotide coding sequence.
24 . A method comprising producing a protein comprising: producing a transgenic avian containing in its genome a hybrid promoter comprising an LTR component and a promoter component wherein the hybrid promoter is operably linked to a protein coding sequence and the protein is packaged into a hard shell egg laid by the avian.
25 . The method of claim 24 wherein the protein is not normally produced in an avian.
26 . The method of claim 24 wherein the protein is a therapeutic protein.